AlzeCure Pharma AB (publ), a pharmaceutical company, announced that the company has chosen a candidate drug (CD) and started the preclinical development phase with the company's preventive and disease-modifying candidate drug Alzstatin ACD680.
ACD680 is being developed within AlzeCure's Alzstatin platform, with the aim of developing a preventive and disease-modifying drug for the early treatment of Alzheimer's disease. In the project, a CD has now been selected which will continue into the preclinical development program, which includes preclinical safety and tolerability studies, as well as formulation work and stability testing.
In Alzheimer's disease, a protein, amyloid beta (A
